Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study

• Príomhchruthaitheoirí: Boel Mörck (Údar), Rille Pullerits (Údar), Mats Geijer (Údar), Tomas Bremell (Údar), Helena Forsblad-d'Elia (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Hindawi Limited, 2013-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

The rationale of the study was to evaluate the efficacy of infliximab (IFX) treatment in patients with ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension sustains the treatment effect. Nineteen patients were included and treated with IFX 5 mg/kg every 6 we...